Cover image

Cover Lung adenocarcinomas harboring specific somatic mutations in the exons encoding the kinase domain of EGFR are highly sensitive to EGFR tyrosine kinase inhibitors such as gefitinib or erlotinib, but acquired resistance usually develops after about a year of therapy. In this issue, the mechanisms of acquired resistance to such targeted therapies through next-generation sequencing of paired drug-sensitive and -resistant lines are investigated. (Cover concept by Hailing Jin, illustration by Jennifer Wilkins, Kins Studio, kinsstudioart@gmail.com. [For details, see Jia et al., pp. 1434–1445.])

This issue is dedicated to the memory of Debra Banninger (1956–2013), former Production Editor for Genome Research, Cold Spring Harbor Laboratory Press colleague, and friend.